Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The company showcased three core programs developed through this platform
Extended lab space for product development, customer demos, and training
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Reaffirms Lupin’s commitment to sustainable resource management
Dr. Muthu was last associated with Mankind Pharma
Subscribe To Our Newsletter & Stay Updated
